Scinai Immunotherapeutics (SCNI) Long-Term Investments (2015 - 2016)
Scinai Immunotherapeutics (SCNI) reported Long-Term Investments of $533000.0 for Q4 2016, up 1.52% on a YoY basis from $525000.0 in Q1 2016, and up 1.52% sequentially from $525000.0 in Q4 2015.
Scinai Immunotherapeutics (SCNI) Long-Term Investments (2015 - 2016) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 2 years of Long-Term Investments data on file, last reported at $533000.0 in Q4 2016.
- For the quarter ending Q4 2016, Long-Term Investments rose 1.52% year-over-year to $533000.0; the trailing twelve-month figure through Dec 2016 stood at $533000.0 (up 1.52% YoY), and the FY2016 full-year result was $533000.0, up 1.52% from the prior year.
- Long-Term Investments improved to $533000.0 in Q4 2016, from $525000.0 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $533000.0 in Q4 2016 to a low of $525000.0 in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Scinai Immunotherapeutics | 352,860.00 | -3.11 Bn | -1.12 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 533,000.00 |
| Dec 31, 2015 | 525,000.00 |